Clinical trials: Gemcitabine
Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Study of Cemiplimab in Adults With Cervical Cancer
The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either…
- Trial name
- NCT03257267
- Testing
- Cemiplimab, Investigator Choice (IC) Chemotherapy
- Where
- 105 sites in United States, Australia and 12 more
- Volunteers
- 608 people
- Sponsor
- Regeneron Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, docetaxel, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00459836
- Testing
- PR-104, docetaxel, gemcitabine hydrochloride
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 42 people
- Sponsor
- Proacta, Incorporated
Nasopharyngeal Carcinoma
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients.
- Trial name
- VANCE (NCT02578641)
- Testing
- autologous EBV specific Cytotoxic T cells, combination IV gemcitabine and IV carboplatin (AUC2)
- Where
- 30 sites in United States, Malaysia and 3 more
- Volunteers
- 330 people
- Sponsor
- Tessa Therapeutics
Pancreatic Neoplasms, Cholestasis
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
The purpose of this study is to determine the safety and pharmacokinetic profile of nab®-paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile…
- Trial name
- NCT02267707
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 6 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- Celgene
Pancreatic Neoplasms
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are…
- Trial name
- NCT00219557
- Testing
- Gemcitabine, AG-013736
- Where
- 38 sites in United States, Belgium and 6 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
This study is open to adults with specific types of advanced soft tissue sarcoma. People with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) can join the study if they have a normal version of the TP53 gene.
- Conditions
- Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
- Trial name
- NCT06370871
- Testing
- Brigimadlin, Ezabenlimab, Gemcitabine
- Sponsor
- Boehringer Ingelheim
Metastatic Pancreatic Cancer
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
The goal of this study is to identify the maximum tolerated dose and dose-limiting side effects of LCL161 in combination with gemcitabine and nab-paclitaxel and to provide safety data in patients with measurable metastatic…
- Trial name
- NCT01934634
- Testing
- LCL161, Gemcitabine, nab-Paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Oncology Research
Advanced or Metastatic Urothelium Cancer
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or…
- Trial name
- NCT05754853
- Testing
- MRG002, Docetaxel Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Shanghai Miracogen Inc.
Pancreatic Cancer, PDAC
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line…
- Conditions
- Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05355298
- Testing
- AMP945 ascending doses, AMP945 RP2D
- Where
- 13 sites in Australia, South Korea
- Volunteers
- 62 people
- Sponsor
- Amplia Therapeutics Limited
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery.
- Trial name
- NCT06730009
- Testing
- SLOG + Allogeneic NK cell, SLOG chemotherapy
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Medigen Biotechnology Corporation
Pancreatic Cancer
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic…
- Trial name
- NCT02551991
- Testing
- nal-IRI, 5 fluorouracil, Leucovorin
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 56 people
- Sponsor
- Ipsen
Neoplasms, Ovarian Neoplasms
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and…
- Conditions
- Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
- Trial name
- NCT01279291
- Testing
- KHK2866, Gemcitabine and Carboplatin, paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Neoplasms
Phase I Perifosine and Gemcitabine Study
This is a study of the drug perifosine in combination with Gemcitabine. Perifosine is an oral anti-cancer agent that has been used in more than 140 people, but has not been combined with other drugs before this study.
- Trial name
- NCT00398697
- Testing
- Perifosine, Gemcitabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AEterna Zentaris
KRAS Activating Mutation, Metastatic Cancer
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously…
- Conditions
- KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic
- Trial name
- RAMP205 (NCT05669482)
- Testing
- avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Verastem, Inc.
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Trial name
- SunRISe-2 (NCT04658862)
- Testing
- Cetrelimab, TAR-200, Cisplatin
- Where
- 290 sites in United States, Argentina and 23 more
- Volunteers
- 518 people
- Sponsor
- Janssen Research & Development, LLC
Triple Negative Breast Cancer
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Primary Endpoint of this Study: To compare Progression-Free Survival (PFS) (as assessed by a Blinded Independent Review Committee [BIRC] based on Response Evaluation Criteria in Solid Tumors [RECIST v1.1]) between JSKN016 and…
- Trial name
- NCT07533123
- Testing
- JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection
- Where
- China
- Volunteers
- 364 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Biliary Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced…
- Trial name
- NCT04809142
- Testing
- TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection
- Where
- 17 sites in China
- Volunteers
- 392 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Neoplasms, Cancer of the Breast
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle…
- Conditions
- Breast Neoplasms, Cancer of the Breast, Breast Cancer
- Trial name
- NCT00191373
- Testing
- Gemcitabine, Trastuzumab
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.